Puma Biotechnolgy Triples on Trial Data, Still Room to Run?

Shares of Puma Biotechnology (PBYI) have more than tripled after strong results for its breast cancer treatment in a drug trial. Leerink’s Howard Liang and team explain why: Special to The Chronicle Although we did not see a positive neratinib ExteNET outcome in adjuvant breast cancer (met both primary and second endpoints with statistical significance) [...]